409 related articles for article (PubMed ID: 19224856)
1. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
3. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Mello-Grand M; Singh V; Ghimenti C; Scatolini M; Regolo L; Grosso E; Zambelli A; Da Prada GA; Villani L; Fregoni V; Baiardi P; Marsoni S; Miller WR; Costa A; Chiorino G
Breast Cancer Res Treat; 2010 Jun; 121(2):399-411. PubMed ID: 20428938
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
[TBL] [Abstract][Full Text] [Related]
6. Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Kendall A; Anderson H; Dunbier AK; Mackay A; Dexter T; Urruticoechea A; Harper-Wynne C; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):855-63. PubMed ID: 18398027
[TBL] [Abstract][Full Text] [Related]
7. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
8. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
9. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
10. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Bhatnagar AS
Breast; 2006 Feb; 15 Suppl 1():S3-13. PubMed ID: 16500235
[TBL] [Abstract][Full Text] [Related]
11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
14. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
[TBL] [Abstract][Full Text] [Related]
15. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
16. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.
Miller WR; Larionov A; Anderson TJ; Walker JR; Krause A; Evans DB; Dixon JM
Cancer; 2008 Feb; 112(3 Suppl):689-694. PubMed ID: 18072233
[TBL] [Abstract][Full Text] [Related]
17. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Miller WR; Larionov A
Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
[TBL] [Abstract][Full Text] [Related]
19. Letrozole.
Dellapasqua S; Colleoni M
Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):251-9. PubMed ID: 20095792
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Chow LW; Yip AY; Loo WT; Toi M
Cancer Lett; 2008 Apr; 262(2):232-8. PubMed ID: 18248884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
